GeoVax Labs, Inc.

Name: GeoVax Labs, Inc. standardized financial statements, quarterly
Creator: Listed

GOVXNasdaqCIK 832489HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026

Operating income−$4.4m, Q2 FY2026

Net income−$4.4m, Q2 FY2026

GeoVax Labs, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	0.0	0.0	0.0	301	2,789	864	1,637	852	0.0	0.0	0.0	0.0
Research and development	$k	6,948	6,234	4,426	4,277	7,403	7,608	5,355	4,729	5,044	2,994	3,903	3,111
Operating income	$k	(8,600)	(7,694)	(5,883)	(5,062)	(5,855)	(8,344)	(5,405)	(5,419)	(6,373)	(4,442)	(5,273)	(4,442)
Interest expense	$k	0.0	0.0	not reported	7.3	14.1	0.0	not reported	0.0	0.0	0.0	not reported	not reported
Income tax	$k	0.0	not reported	0.0	0.0	0.0	not reported	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$k	(8,409)	(7,592)	(5,850)	(5,064)	(5,815)	(8,263)	(5,358)	(5,370)	(6,319)	(4,418)	(5,262)	(4,427)
Diluted EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Basic EPS	$ per share	(4.75)	not reported	(2.47)	(1.99)	(0.91)	not reported	(11.20)	(8.74)	(0.31)	not reported	(2.62)	(0.97)

Balance sheet

Cash and equivalents$3.1m, Q2 FY2026

Shareholders' equity$1.8m, Q2 FY2026

GeoVax Labs, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	12.7	6.5	0.8	1.6	8.6	5.5	7.4	3.1	5.0	3.1	1.3	3.1
Current assets	$m	14.8	7.9	2.9	3.8	10.9	7.9	10.6	5.1	6.5	5.3	2.4	4.2
Total assets	$m	16.2	9.3	3.4	4.1	11.1	8.2	10.8	5.4	6.7	6.3	3.0	4.6
Current liabilities	$m	7.1	3.5	3.3	6.4	2.6	3.1	2.9	2.5	1.8	1.9	2.3	2.7
Total liabilities	$m	not reported	not reported	not reported	not reported	not reported	3.1	not reported	not reported	not reported	2.5	2.5	2.9
Shareholders' equity	$m	9.1	5.8	0.1	(2.3)	8.5	5.0	7.9	2.8	4.9	3.8	0.5	1.8

Cash flow

Operating cash flow−$3.7m, Q2 FY2026

Capital expenditure$0, Q2 FY2026

GeoVax Labs, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(5.1)	(10.3)	(5.7)	(1.9)	(9.3)	(7.8)	(6.0)	(4.3)	(6.2)	(5.0)	(3.5)	(3.7)
Capital expenditure	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. Listed shows no prices and gives no investment advice.